Tags : Heart Failure Neuromodulation Device

CVRx’s Barostim Neo Device Receives the US FDA’s Approval as

Tuba Khan August 19, 2019

Shots: The US FDA’s PMA is based on P-III BeAT-HF study confirming the safety of Barostim Neo and its effectiveness in improving symptoms in 264 patients with chronic heart failure. […]readmore

Tags : Heart Failure Neuromodulation Device

CVRx’s Barostim Neo Device Receives the US FDA’s Approval as

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Heart Failure Neuromodulation Device

﻿CVRx’s Barostim Neo Device Receives the US FDA’s Approval as

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

CVRx’s Barostim Neo Device Receives the US FDA’s Approval as